TrialHematological oncology2021

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.

Gian Matteo Rigolin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.